ADAntonino Daidone

Antonino Daidone

*This is an algorithmically generated author record based on publicly available information.

Antonino Daidone has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Applications of Artificial Intelligence in Prostate Cancer Radiotherapy: A Narrative Review

    by Antonio Piras, Albert Comelli, Andrea D’Aviero, Nino Dispensa, Nicola Pavan, Fabrizio Di Maida, Davide Cusumano, Calogero Casà, Antonino Daidone, Viviana Benfante, et al.

    Introduction: Radiotherapy (RT) plays a crucial role in the management of prostate cancer (PC). Artificial intelligence (AI) is reshaping cancer care by providing innovative tools for diagnosis, treatment optimization, and outcome prediction. This review provides an end-to-end synthesis of AI applications across the prostate RT workflow, critically evaluating their clinical maturity, level of evidence, and current barriers to real-world implementation. Methods: A literature review of PubMed/MEDLINE and Embase was conducted to investigate the impact of AI on prostate RT. Only original articles published up to 1 August 2025 were included. The 27 selected studies were categorized into the following clusters: adaptive radiotherapy, autocontouring, autoplanning, prediction, synthetic computed tomography (CT), quality assurance (QA), and tracking. Results: Autocontouring was the most represented cluster, followed by prediction, autoplanning, and adaptive RT. Fewer studies addressed tracking, QA, and synthetic CT. Conclusions: AI shows significant potential across multiple phases of the prostate RT workflow; however, most evidence is based on retrospective or technical validation studies. Further research is required to establish clinical benefit and support integration into personalized treatment strategies.


  • Open Access

    Multifocal Cutaneous Rosai-Dorfman Disease Treated With Localized Radiotherapy

    by Gaetano Licata, Giovanni Spanò, Domenico Messina, Antonino Daidone, Leonardo Zichichi

    Citation: Licata G, Spanò G, Messina D, Daidone A, Zichichi L. Multifocal Cutaneous Rosai-Dorfman Disease Treated With Localized Radiotherapy. Dermatol Pract Concept. 2024;14(1):e2024043. DOI: https://doi.org/10.5826/dpc.1401a43 Accepted: August 17, 2023; Published: January 2024 Copyright: ©2024 Licata et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited. Funding: None. Competing interests: None. Authorship: All authors have contributed significantly to this publication. Corresponding author: Dr. Gaetano Licata, MD, Dermatology Unit, Ospedale S.A. Abate, Trapani, Via Cosenza 82, 91016, Erice (TP), Italy. Phone: 3276215976 E-mail gaetano.licata89@gmail.com Keywords : Cutaneous Rosai-Dorfman, radiotherapy, rare disease, clinical practice This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

  • Open Access

    Stereotactic Body Radiotherapy for Lymph-Nodal Oligometastatic Prostate Cancer: A Multicenter Retrospective Experience

    by Francesco Cuccia, Maria Tamburo, Antonio Piras, Gianluca Mortellaro, Arianna Iudica, Antonino Daidone, Manuela Federico, Valentina Zagardo, Gianluca Ferini, Francesco Marletta, et al.

    Background: The favorable role of SBRT for lymph-nodal oligometastases from prostate cancer has been reported by several retrospective and prospective experiences, suggesting a more indolent natural history of disease when compared to patients with bone oligometastases. This retrospective multicenter study evaluates the outcomes of a cohort of patients treated with stereotactic body radiotherapy for lymph-nodal oligometastases. Methods: Inclusion criteria were up to five lymph-nodal oligometastases detected either with Choline-PET or PSMA-PET in patients naïve for ADT or already ongoing with systemic therapy and at least 6 Gy per fraction for SBRT. Only patients with exclusive lymph-nodal disease were included. The primary endpoint of the study was LC; a toxicity assessment was retrospectively performed following CTCAE v4.0. Results: A total of 100 lymph-nodal oligometastases in 69 patients have been treated with SBRT between April 2015 and November 2022. The median age was 73 years (range, 60–85). Oligometastatic disease was mainly detected with Choline-PET in 47 cases, while the remaining were diagnosed using PSMA-PET, with most of the patients treated to a single lymph-nodal metastasis (48/69 cases), two in 14 cases, and three in the remaining cases. The median PSA prior to SBRT was 1.35 ng/mL (range, 0.3–23.7 ng/mL). Patients received SBRT with a median total dose of 35 Gy (range, 30–40 Gy) in a median number of 5 (range, 3–6) fractions. With a median follow-up of 16 months (range, 7–59 months), our LC rates were 95.8% and 86.3% at 1 and 2 years. DPFS rates were 90.4% and 53.4%, respectively, at 1 and 2 years, with nine patients developing a sequential oligometastatic disease treated with a second course of SBRT. Polymetastatic disease-free survival (PMFS) at 1 and 2 years was 98% and 96%. Six patients needed ADT after SBRT for a median time of ADT-free survival of 15 months (range, 6–22 months). The median OS was 16 months (range, 7–59) with 1- and 2-year rates of both 98%. In multivariate analysis, higher LC rates and the use of PSMA-PET were related to improved DPFS rates, and OS was significantly related to a lower incidence of distant progression. No G3 or higher adverse events were reported. Conclusions: In our experience, lymph-nodal SBRT for oligometastatic prostate cancer is a safe and effective option for ADT delay with no severe toxicity.


  • Open Access

    The Added Value of [18F]Choline PET/CT in Low-Risk Prostate Cancer Staging: A Case Report

    by Antonio Piras, Riccardo Laudicella, Luca Boldrini, Andrea D’aviero, Antonella Sanfratello, Antonino La Rocca, Salvatore Scurria, Giuseppe Salamone, Pierpaolo Alongi, Tommaso Angileri, et al.

    In the management of prostate cancer (PCa), correct staging is crucial in order to assess the right therapeutic approach. [18F]Choline PET/CT has been shown to provide more accurate staging information than conventional imaging approaches. The aim of this paper is to provide a real practice demonstration of the impact of [18F]Choline PET/CT on low-risk prostate cancer staging and clinical management. We report a 64-year-old man with biochemical PCa recurrence diagnosis after transurethral resection of the prostate. The patient, after the detection of an increased level of PSA, underwent multi-parametric prostate magnetic resonance imaging (mpMRI) that did not show evidence of disease. The patient was admitted to perform [18F]Choline PET/CT that showed a macroscopic prostate recurrence. Patient underwent photon external beam radiation therapy (EBRT) treatment, and [18F]Choline PET/CT was also used to define treatment volumes. At 3- and 6-month clinical follow-up evaluations, no late toxicity was detected and a significant reduction in PSA value was shown. Therefore, our case highlights the potential usefulness of [18F]Choline PET/CT for the staging of low-risk prostate cancer and its impact on the management and quality of life of such patients. The presented case should urge the scientific community to enhance larger and multicentric studies, assessing more extensively the potential impact of [18F]Choline PET/CT in this clinical scenario.


  • Open Access

    Patterns of Care for Breast Radiotherapy in Italy: Breast IRRadiATA (Italian Repository of Radiotherapy dATA) Feasibility Study

    by Antonella Ciabattoni, Fabiana Gregucci, Giuseppe D’ermo, Alessandro Dolfi, Francesca Cucciarelli, Isabella Palumbo, Simona Borghesi, Alessandro Gava, Giovanna Maria Cesaro, Antonella Baldissera, et al.

    Aim. Breast IRRADIATA (Italian Repository of RADIotherapy dATA) is a collaborative nationwide project supported by the Italian Society of Radiotherapy and Clinical Oncology (AIRO) and the Italian League Against Cancer (LILT). It focuses on breast cancer (BC) patients treated with radiotherapy (RT) and was developed to create a national registry and define the patterns of care in Italy. A dedicated tool for data collection was created and pilot tested. The results of this feasibility study are reported here. Methods. To validate the applicability of a user-friendly data collection tool, a feasibility study involving 17 Italian Radiation Oncology Centers was conducted from July to October 2021, generating a data repository of 335 BC patients treated between January and March 2020, with a minimum follow-up time of 6 months. A snapshot of the clinical presentation, treatment modalities and radiotherapy toxicity in these patients was obtained. A Data Entry Survey and a Satisfaction Questionnaire were also sent to all participants. Results. All institutions completed the pilot study. Regarding the Data Entry survey, all questions achieved 100% of responses and no participant reported spending more than 10 min time for either the first data entry or for the updating of follow-up. Results from the Satisfaction Questionnaire revealed that the project was described as excellent by 14 centers (82.3%) and good by 3 (17.7%). Conclusion. Current knowledge for the treatment of high-prevalence diseases, such as BC, has evolved toward patient-centered medicine, evidence-based care and real-world evidence (RWE), which means evidence obtained from real-world data (RWD). To this aim, Breast IRRADIATA was developed as a simple tool to probe the current pattern of RT care in Italy. The pilot feasibility of IRRADIATA encourages a larger application of this tool nationwide and opens the way to the assessment of the pattern of care radiotherapy directed to other cancers.